| Name | Title | Contact Details |
|---|
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, chemical and biopharmaceutical industries that have in-house genomic capabilities. Dyadic will also collaborate with companies whose genomic capabilities are limited, discovering and expressing biological materials for these strategic partners. In addition, Dyadic, using these proprietary systems, will continue to commercialize enzymes for use in targeted markets, including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries. Dyadic expects to generate revenue from its product sales, revenue generated from research and development services and funding as well as revenue generated from licensing and other strategic collaborations in the form of milestone and royalty payments.
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.
LabConnect is a global provider of clinical trial laboratory services, established in 2002 and based in Seattle, Washington. The company specializes in central laboratory solutions and functional service provider (FSP) support, partnering with pharmaceutical, biotechnology, and clinical research organizations. LabConnect has successfully managed over 1,900 clinical studies across 93 countries, emphasizing agility and innovation through a network of more than 30 laboratory locations worldwide. The company offers a range of services, including project management, a global testing network with over 10,000 validated tests, and comprehensive logistics and biorepository solutions. LabConnect also provides bioanalytical expertise and customized staffing for scientific project management. Its product offerings include customized lab kits for trial sites and integrated data management systems for real-time analytics. With a strong client portfolio that includes major pharmaceutical firms, LabConnect is positioned as a reliable partner for complex clinical trials.
The Boston Biomedical Research Institute (BBRI) is dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases. The areas of investigation concern the structure and function of muscle proteins,